Skip to main content
TTrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor.
RECRUITINGOBSERVATIONAL

Neutrophil to Lymphocyte Ratio in Acute Exacerbation of Chronic Obstructive Pulmonary Disease

Neutrophil to Lymphocyte Ratio in Acute Exacerbation of Chronic Obstructive Pulmonary Disease: A Marker of Severity and Prognosis

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

Chronic obstructive pulmonary disease (COPD) stands as one of the leading causes of mortality worldwide. Acute exacerbations of COPD (AECOPD) lead to rapid respiratory function decline and worsened disease status. Despite recent studies, the ability of the neutrophil-to-lymphocyte ratio (NLR) to predict outcomes in patients with COPD remains controversial. It remains controversial whether NLR can predict clinical outcomes in hospitalized patients with AECOPD. Therefore, this study was conducted to investigate the predictive value of NLR for severity, adverse outcomes in hospitalized patients with AECOPD, and predicting treatment response in patients with AECOPD

Who May Be Eligible (Plain English)

Who May Qualify: - Patients aged 18 and above, Patients who will be admitted at the Chest department, Ain-Shams University Hospitals, diagnosed with AECOPD based on the Global Initiative for Chronic Obstructive Lung Disease 2024 criteria Who Should NOT Join This Trial: - Patients who refused treatment. - COPD patients with Malignancy, hematological disorders Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: * Patients aged 18 and above, Patients who will be admitted at the Chest department, Ain-Shams University Hospitals, diagnosed with AECOPD based on the Global Initiative for Chronic Obstructive Lung Disease 2024 criteria Exclusion Criteria: * Patients who refused treatment. * COPD patients with Malignancy, hematological disorders

Treatments Being Tested

OTHER

neutrophil lymphocyte ratio in COPD patients

Neutrophil lymphocyte ratio in determining severity and prognosis in exacerbation of COPD patients

Locations (1)

Ain Shams University
Cairo, Abbasyea, Egypt